- Home
- PRLD vs ALAR Comparison
PRLD vs ALAR Comparison
Compare PRLD & ALAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- ALAR
- Stock Information
- Founded
- PRLD 2016
- ALAR 2013
- Country
- PRLD United States
- ALAR Israel
- Employees
- PRLD N/A
- ALAR N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- ALAR Computer Software: Prepackaged Software
- Sector
- PRLD Health Care
- ALAR Technology
- Exchange
- PRLD Nasdaq
- ALAR Nasdaq
- Market Cap
- PRLD 50.1M
- ALAR 45.3M
- IPO Year
- PRLD 2020
- ALAR 2018
- Fundamental
- Price
- PRLD $0.89
- ALAR $6.76
- Analyst Decision
- PRLD Strong Buy
- ALAR Strong Buy
- Analyst Count
- PRLD 2
- ALAR 1
- Target Price
- PRLD $4.50
- ALAR $11.00
- AVG Volume (30 Days)
- PRLD 137.5K
- ALAR 130.2K
- Earning Date
- PRLD 05-06-2025
- ALAR 05-29-2025
- Dividend Yield
- PRLD N/A
- ALAR N/A
- EPS Growth
- PRLD N/A
- ALAR N/A
- EPS
- PRLD N/A
- ALAR 0.07
- Revenue
- PRLD $7,000,000.00
- ALAR $30,581,000.00
- Revenue This Year
- PRLD N/A
- ALAR N/A
- Revenue Next Year
- PRLD N/A
- ALAR $12.28
- P/E Ratio
- PRLD N/A
- ALAR $11.37
- Revenue Growth
- PRLD N/A
- ALAR 4.67
- 52 Week Low
- PRLD $0.61
- ALAR $5.45
- 52 Week High
- PRLD $6.80
- ALAR $46.69
- Technical
- Relative Strength Index (RSI)
- PRLD 51.42
- ALAR 41.20
- Support Level
- PRLD $0.77
- ALAR $7.42
- Resistance Level
- PRLD $1.00
- ALAR $8.57
- Average True Range (ATR)
- PRLD 0.11
- ALAR 0.65
- MACD
- PRLD -0.01
- ALAR -0.08
- Stochastic Oscillator
- PRLD 37.18
- ALAR 9.01
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.